Member Info for Rocket79

Over a mil traded already. Follow the money... insiders buying in imo. Level 2 order book looking very strong.

Peel Hunt added its published risked/unrisked valuation for Anchois stands at 23p/94p, indicating the potential prize on offer in the event of full commercial exploitation of Anchois’ PHe c.360Bcf 2C gas resource.

Buy with a target price of 15p is the broker’s view.

Peel Hunt added its published risked/unrisked valuation for Anchois stands at 23p/94p, indicating the potential prize on offer in the event of full commercial exploitation of Anchois’ PHe c.360Bcf 2C gas resource.

Buy with a target price of 15p is the broker’s view.

These should reach 150p on this data alone. They are in discussions with potential partners.

With the volumes we have been seeing these are going to rerate today. Seller is done imo.

150p target. Similar to rise in Feb 2021. Buy

#gdr
Investor relations reply when asked if CE could come sooner.
The description of the 10 days in the agreements is not as specific as to answer that question. The latest is 14th, but it could be earlier.
 
Regards,

GDR official rns for CE certification & distribution deals on the way!

No stopping this now, everyone wants in before the weekend as news likely to land early next week

Sat at only £36m mcap with £9.9m in cash - huge rise on way here similar to NCYT

These will be over 100p on once we get CE approval. 6 Trading days left...then boooom

Look at the rise Feb 2021. This is exactly the same. This will rerate. CE approval in 10 working days. Could possibly get other news before also.

CE approval in 10 working days

This will rise all this week. 150p very soon imo
#GDR Peel Hunt: with an EV of c.£19m its technology and assets (eg point of care assays for antibiotic induced hearing loss and this coronavirus test) are deeply discounted at current valuations. Today’s update is a timely reminder of genedrive’s capability in assay designs.

Once this hits 150p, 300p is next target.

Buy and hold

#GDR Peel Hunt: with an EV of c.£19m its technology and assets (eg point of care assays for antibiotic induced hearing loss and this coronavirus test) are deeply discounted at current valuations. Today’s update is a timely reminder of genedrive’s capability in assay designs.

This is going to rerate this week

#GDR Peel Hunt: with an EV of c.£19m its technology and assets (eg point of care assays for antibiotic induced hearing loss and this coronavirus test) are deeply discounted at current valuations. Today’s update is a timely reminder of genedrive’s capability in assay designs.

This will he a multi bagger. This was 300p on lesser news. Genedrive is also not just a covid play.

Run upto 150p in next 2 weeks in anticipation of CE...Remember this can do 20-30 % a day

If GDR can get their POC test which is just as accurate as a PCR test developed and in production then we would be worth more than NCYT imo